RPL21

Large ribosomal subunit protein eL21 · P46778 · RPL21 on Sugi Atlas →

3,671 patent compounds predicted against RPL21, 1,923 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL21 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES	PHASE3	UNKNOWN
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies	PHASE1	WITHDRAWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Shwachman Diamond Syndrome Registry and Study	nan	RECRUITING
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPL21 binder may also engage these)

Protein	Name	Similarity
P49666	—	1.000	P49666 →
G1SHQ2	—	1.000	G1SHQ2 →
O09167	—	1.000	O09167 →
Q6QN05	—	1.000	Q6QN05 →
A5JSS2	—	1.000	A5JSS2 →
P20280	—	0.995	P20280 →
P47832	—	0.946	P47832 →
P61255	—	0.943	P61255 →
G1SQH0	—	0.943	G1SQH0 →
RPL26	Large ribosomal subunit protein uL24	0.941	landscape →
P61257	—	0.941	P61257 →
P61256	—	0.940	P61256 →
P12749	—	0.940	P12749 →
P62912	—	0.936	P62912 →
Q76KA3	—	0.936	Q76KA3 →
E2RKA8	—	0.936	E2RKA8 →
P62911	—	0.934	P62911 →
Q6QAT0	—	0.934	Q6QAT0 →
Q9UNX3	—	0.933	Q9UNX3 →
Q4R723	—	0.933	Q4R723 →
Q56K03	—	0.932	Q56K03 →
RPL32	Large ribosomal subunit protein eL32 (60S rib	0.932	landscape →
P14115	—	0.930	P14115 →
Q56JV1	—	0.930	Q56JV1 →
P61251	—	0.929	P61251 →
RPS26	Small ribosomal subunit protein eS26 (40S rib	0.929	landscape →
P62855	—	0.929	P62855 →
G1SNY0	—	0.928	G1SNY0 →
P49171	—	0.928	P49171 →
Q8BMJ3	—	0.923	Q8BMJ3 →